Jul 6, 2021
Vivpro Announces New Appointment To Board Of Advisors: Dr. Katie Laessig
Vivpro Corporation announced today that it has appointed Dr. Katie Laessig, SVP Global Regulatory Affairs, Antios Therapeutics to its Advisory Board.
”We are excited to work with Dr. Laessig and leverage her industry and regulatory experience to deliver unique value to pharmaceutical and biotech,” said Dr. Joga Gobburu, President Vivpro Corporation. ”I look forward to working with Katie again. Katie’s deep experience in regulatory and development will helpVivprofurther the mission to re-imagine drug development. Katie is a founding member of the Vivpro Advisory Board. Vivpro Advisory Board is a critical step in our journey as we enter a new stage of product growth, we would like to work with passionate individuals like Katie to validate and guide our niche market strategy and customer value.”
This is one of several appointments that will be announced over the next few weeks. Vivpro will regularly evaluate the membership to ensure it includes diverse skills, experience and perspectivenecessary to drive growth for all Vivpro customers.
”It is an honor to join the Vivpro advisory board as I see the Vivpro platform can help pharmaceuticals and biologics industry deliver strategic, regulatory, and clinical development planning including regulatory interactions to increase probability of success,” said Dr. Katie Laessig.
About Dr. Katie Laessig
Dr. Laessig has more than 20 years of experience in pharmaceutical regulatory roles both in industry and for the U.S. FDA. Before joining Antios, she served as Vice President, Therapeutic Strategy, Strategic Drug Development at IQVIA where she delivered strategic regulatory and clinical development planning for pharmaceuticals and biologics, including support for regulatory interactions, across a range of therapeutic areas for the IQVIA’s biotechnology and pharmaceutical customers. Before that, she was SVP, Regulatory Affairs, Medical Safety and Quality Assurance at RRD International, LLC, where she provided strategic and tactical regulatory, clinical, and development evaluation and direction to product development programs undertaken by RRD for its client companies. From 1999 to 2015, Dr. Laessig served in multiple roles of increasing responsibility at the U.S. FDA including Medical Review Officer and MedicalTeam Leader, Division of Antiviral Products, and Deputy Director, Division of Anti-Infective Products. From 2000-2016, she volunteered once weekly at the Whitman Walker Clinic in Washington, DC, the city’s largest provider of HIV/AIDS care.
Dr. Laessig earned her M.D. from the University of Maryland School of Medicine and a B.A. in Biology from Cornell University.
